布鲁克 2025年度报告

ANNUAL REPORT Innovation with Impact – Innovation with Integrity Dear Fellow Bruker Shareholders, The year 2025 was an important transition year in Bruker’stransformation, as we continued to develop our differentiated portfoliofor leadership in the post-genomic era, expanding our Project Accelerate Despite a challenging macroeconomic and academic end-marketbackdrop in 2025, accompanied by headwinds from new tariffs and asteep decline of the USD, we strengthened our leadership positions inpost-genomic solutions for disease biology research and drug discovery, We also invested in novel opportunities in clinical microbiology andmolecular diagnostics, as well as in AI-lab automation, software anddigitalization, while increasing revenue contributions from service,software, consumables, and other recurring revenue streams.Importantly, we also started and expanded major cost-out initiativesto enable a rebound in margins and profitability, and over time drivetowards EBITDA margins in the mid-20% range with an above-marketorganic revenue growth profile – which was challenged in 2025.In 2025, we delivered revenues of $3.44 billion, up 2.1% year over Alongside the integration of our 2024 acquisitions, we improved productivity throughout the business to supportfuture margin expansion. The unprecedented scale, portfolio breadth, and strategic positioning leaves Brukerprepared to deliver resilient, high-quality growth, supported by key innovations with impact, more recurring Project Accelerate 3.0 (PA3)evolves our focus from high-value research instrumentation towards next-generationworkflow solutions for post-genomic disease research and drug discovery, andPA3also expands our positionsin clinical microbiology and molecular diagnostics, as well as in automated digital and AI-ready laboratories, andadjacent analytical workflows that leverage our core high-performance measurement instruments portfolio. This Our major acquisitions in 2024 are central to this expansion: ELITech adds molecular diagnostics capabilities thatcomplement our microbiology franchise and supports consumables pull-through and recurring testing revenue.Chemspeed expands our presence in R&D and QC laboratory automation, where software-enabled workflows In 2025, we advanced our leadership in post-genomic discovery with launches such asCosMxWhole HumanTranscriptome in spatial biology, andtimsOmni-enabled Functional Proteomics 2.0, expanding our crucial role in Together, these additions strengthen Bruker’s position across research, diagnostics, and quality control, while at The Next Phase of Bruker’s Evolution As we move forward, we expect the mix shift towards Project Accelerate 3.0 areas to support marginprogression and earnings growth. Bruker is shaping its portfolio not only for scientific research market relevance,but also for greater resilience and improved profitability. Innovation with impact and integrity remains the I am looking forward to providing updates on our progress in this next phase of our portfolio transformation and Sincerely, Frank H. LaukienChairman, President & CEOBruker Corporation BRUKER CORPORATIONANNUAL REPORT